Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Hepatology. 2020 Aug;72(2):379–388. doi: 10.1002/hep.31298

Figure 4: Imatinib treatment reduces AKT and cyclin D1 expression in HCV-HCC PDX tumors.

Figure 4:

Panel A: A schematic representation of c-Kit downstream molecules. Panel B: Lysates from control PDX tumors and imatinib-treated tumors were subjected to western blot analysis for phospho-Akt (Thr308) expression using specific antibody. The blot was reprobed for total AKT and actin (for comparison of protein load) using specific antibodies. Densitometric scanning results are presented as bar diagram. Panel C: Lysates from control PDX tumors and imatinib-treated tumors were subjected to western blot analysis for cyclin D1 expression using specific antibody. The blot was reprobed with antibody to actin for comparison of protein load. Densitometric scanning results are presented as bar diagram. *p < 0.05.